



(Please scan this QR Code to view the Prospectus)

AMANTA HEALTHCARE LIMITED

Our Company was originally incorporated on December 21, 1994 as Marck Parenterals (India) Limited with RoC, Gujarat, at Ahmedabad by converting the existing Partnership firm "Marck Parenterals (India)" under Part IX of the Companies Act, 1956 and received the Certificate for Commencement of Business on January 06, 1995. Subsequently, the name of our Company was changed to "Marck Biosciences Limited" pursuant to a special resolution passed by our shareholders on October 29, 2005. The fresh certificate of incorporation consequent upon change of name was granted on November 02, 2005 by the Registrar of Companies, Gujarat at Ahmedabad. Subsequently, the name of our Company was changed to "Amanta Healthcare Limited" pursuant to a special resolution passed by our shareholders on June 12, 2014, and a fresh certificate of incorporation dated June 24, 2014 issued by the Registrar of Companies Gujarat at Ahmedabad. For further details of the history of our company, kindly refer to section "History and Certain Corporate Matters" beginning on page 355 of the Prospectus.

Registered and Corporate Office: 8th Floor, Shaligram Corporates, C.J. Marg, Ambli, Ahmedabad – 380058, Gujarat, India | Tel: 079 6777600 | Contact Person: Nikhita Dinodia, Company Secretary and Compliance Officer | E-mail: cs@amanta.co.in | Website: www.amanta.co.in
Corporate Identity Number: U24139GJ1994PLC023944

PROMOTERS OF OUR COMPANY: BHAVESH PATEL, VISHAL PATEL, JAYSHREEBEN PATEL, JITENDRAKUMAR PATEL AND MILCENT APPLIANCES PRIVATE LIMITED

Our Company has filed the Prospectus dated September 04, 2025 with the RoC, and the Equity Shares are proposed to be listed on the BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") and trading is expected to commence on September 09, 2025.

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFERING OF 1,00,00,000 EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹126 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹116 PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING ₹ 12,60,00,00,000 LAKHS (THE "ISSUE") COMPRISING OF POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ANCHOR INVESTOR ISSUE PRICE: ₹126 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH
ISSUE PRICE: ₹126 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH
THE ISSUE PRICE IS 12.60 TIMES OF THE FACE VALUE

Risk to Investors

For details, refer to section titled "Risk Factors" on page 29 of the Prospectus.

- Location risk:** Our Company's entire manufacturing facility is located at a single location, and all of the Company's manufactured products are produced from such facility in village Hariyala, district Kheda, Gujarat. Any delay in production at, or shutdown of, our manufacturing facility due to various factors such as shortage of electrical power or water resources, political instability, industrial accidents or machinery breakdowns, severe weather conditions, natural disasters, and outbreak of infectious diseases may in turn adversely affect our business, financial condition and results of operations.
- Supplier risk:** We are significantly dependent on imports of plastic granules being primary packing material and are to that extent exposed to risks including duties placed on imports from other countries or regulatory or market concerns regarding materials sourced from such countries, fluctuations in global commodity prices, and foreign currency exchange fluctuations. A significant proportion of the plastic granules we consume are imported. In the Fiscal 2025, 2024 and 2023, the value of raw material (being plastic granules) imported by us is as follows:

Particulars	Fiscal 2025			Fiscal 2024			Fiscal 2023		
	In ₹ lakhs	% of total materials consumed by us	% of Revenue from Operations	In ₹ lakhs	% of total materials consumed by us	% of Revenue from Operations	In ₹ lakhs	% of total materials consumed by us	% of Revenue from Operations
Plastic granules imported	3,333.74	32.92	12.14	2,746.67	32.08	9.80	3,151.66	31.31	12.16
Other raw material Imported	2.23	0.02	0.01	-	-	-	26.23	0.26	0.10

- Profitability risk:** We may not be able to improve our profit margins and profits in the future. Our Profit and profit margins in the Fiscal 2023, Fiscal 2024 and Fiscal 2025 are as follows:

Particulars	Fiscal 2025	Fiscal 2024	Fiscal 2023
Profit after tax (amount in ₹ lakhs)	1,050.07	363.32	(211.06)
Profit Margin (in %)	3.86%	1.30%	(0.82%)

We have recorded losses in the past and our profit margins are also fluctuating on a YoY basis, we cannot ensure that we will not incur losses in the future or our net profit margins will improve in the future.

Set forth below are details of our Cap Price and Floor Price to earnings ratio and market capitalisation (based on the Cap Price) to revenue from operations multiple, for the years indicated:

Year	Earnings ratio		Market capitalization* to revenue from operations multiples	
	Cap Price	Floor Price	Cap Price	Floor Price
Fiscal year 2025	33.92	32.31	1.78	1.70
Fiscal year 2024	93.04	88.61	1.75	1.66
Fiscal year 2023	(160.17)	(152.54)	1.89	1.80

Notes:

* Market capitalization is calculated as post Issue number of Equity Shares multiplied by Cap Price/Floor Price

- Finance cost risk:** Finance cost of the Company has been very high and finance cost of the company for the Fiscal 2025, Fiscal 2024, and Fiscal 2023 constituted 45.78%, 57.25% and 62.64% of the Restated Earnings before interest, tax, depreciation and amortization (EBITDA). If company is unable to control the finance cost in future, it may adversely affect business, results of operations, financial condition and cash flows.

The details of Company's finance cost and other relevant details are as under:

(in ₹ lakhs)

Particulars	For the Financial Year		
	2025	2024	2023
Finance costs	2,794.79	3,363.79	3,527.02
Restated Earnings before interest, tax, depreciation and amortisation (EBITDA)	6,105.37	5,875.65	5,630.67
Finance cost as % of Restated Earnings before interest, tax, depreciation and amortisation (EBITDA)	45.78	57.25	62.64
Debt to equity ratio	2.02	3.10	3.43

- High debt to equity ratio risk:** Our Company has a high debt to equity ratio which denote our significant outstanding debt and financial obligations and our inability to meet our financial obligations may limit our ability to pursue our business and could adversely affect our business, financial condition, results of operations and cash flows. Our Company has a high debt to equity ratio which denote our significant outstanding debt and financial obligations, if we are unable to service these obligations it could materially affect our financial position. Set forth below are details of our debt to equity ratio and outstanding borrowings:

Particulars	As at and for the Fiscal ended March 31, 2025	As at and for the Fiscal ended March 31, 2024	As at and for the Fiscal ended March 31, 2023
	Debt to equity ratio	2.02	3.10
Total Borrowings (₹ in lakhs)	19,499.61	20,522.91	21,565.85

- Litigation risk:** Our Company and one of our Promoters are involved in certain criminal legal proceedings an adverse outcome of which would materially and adversely affect our Company's business, prospects, operations, financial condition or reputation, irrespective of the amount involved in such litigation. Involvement in this proceeding could divert our management's time and attention and consume financial resources. Further, an adverse judgment in this proceeding could have an adverse impact on our business, results of operations and financial condition. We cannot assure you that this proceeding will be settled in our favour or that no additional liability will arise out of these proceedings.

Name of the Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceeding	Disciplinary actions by the SEBI or Stock Exchanges against our Promoter	Material Civil Litigations	Aggregate Amount Involved (₹ in lakhs)
Company						
By our Company	Nil	-	-	-	Nil	Nil
Against our Company	Nil	17	Nil	-	Nil	1,476.41
Directors (other than Promoters)						
By our Directors	Nil	-	-	-	Nil	Nil
Against our Directors	Nil	Nil	Nil	Nil	Nil	Nil
Promoters						
By our Promoters	Nil	-	-	-	Nil	Nil
Against our Promoters	Nil	Nil	Nil	Nil	Nil	Nil
Key Managerial Personnel						
By our Key Managerial Personnel	Nil	N.A	Nil	N.A	N.A	Nil
Against our Key Managerial Personnel	Nil	N.A	Nil	N.A	N.A	Nil
Senior Managerial Personnel						
By our Senior Managerial Personnel	Nil	N.A	Nil	N.A	N.A	Nil
Against our Senior Managerial Personnel	Nil	N.A	Nil	N.A	N.A	Nil

*In accordance with the Materiality Policy and to the extent quantifiable.

- Quality risk:** Any manufacturing or quality control concerns or our inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by our clients and distributors, which could have an adverse effect on our business, results of operations, financial condition and cash flows. If we experience a product recall or are a party to a product liability case, we may incur considerable expense in litigation. In the past, we have had three instances of products being recalled from markets.

- Foreign currency fluctuation risks:** We are exposed to foreign currency fluctuation risks, particularly in relation to import of raw materials and export of products, which may adversely affect our results of operations, financial condition and cash flows. Set forth below are details of our (i) expenditure on consumption of imported raw material, and (ii) revenue from operations from sales located outside India, in each of the corresponding years:

Particulars	Fiscal 2025			Fiscal 2024			Fiscal 2023		
	(₹ lakhs)	Percentage of total materials sourced (%)	Percentage of revenue from operations (%)	(₹ lakhs)	Percentage of total materials sourced (%)	Percentage of revenue from operations (%)	(₹ lakhs)	Percentage of total materials sourced (%)	Percentage of revenue from operations (%)
Expenditure on consumption of imported raw material	447.41	4.70	1.63	348.25	3.73	1.24	395.98	4.00	1.53

Particulars	Fiscal 2025		Fiscal 2024		Fiscal 2023	
	(₹ lakhs)	Percentage of revenue from operations (%)	(₹ lakhs)	Percentage of revenue from operations (%)	(₹ lakhs)	Percentage of revenue from operations (%)
Revenue from operations outside India	9,083.09	33.06%	8,217.14	29.31%	8,018.51	30.94%

- License suspension risk:** As a manufacturer of pharmaceutical formulations, we are required to comply with the regulations and quality standards stipulated by the regulatory authorities in India and the countries to which we export our products. For instance, our Company received a show cause notice, under Rule 85 of the Drugs & Cosmetics Rules, from the Food and Drugs Control Administration, Gandhinagar, Gujarat on March 11, 2015, due to a report from the Government Analyst, Central Drugs Laboratories, Kolkata. Pursuant to that report one of our products (Sterile Water for Injection IP- batch no. 2F541006) was classified as "Not of Standard Quality Drugs". Our Company responded to the notice vide letter no. Marck/FDA/SVP/NSQ/001, dated March 30, 2015. Subsequently, FDCA, vide an order dated May 18, 2015, suspended our manufacturing license no. G/1080 in form no:28 for a brief period of two days i.e., June 18, 2015, and June 19, 2015.

- Competition risk:** We operate in a market that is highly competitive. If we are unable to respond adequately to the increased competition or pricing pressure we expect to face, we could lose market share and our revenues and profits could decline, which could adversely affect our business. The domestic and international pharmaceutical industry is highly competitive with several major pharmaceutical companies present. Our products face intense competition from products commercialized or under development by competitors in the pharmaceutical industry.

- Customer concentration risk:** We derive a significant part of our revenue from few customers. If one or more of such customers choose not to source their requirements from us or to terminate our contracts or purchase orders, our business, cash flows, financial condition and results of operations may be adversely affected.

The table below sets out the revenue contribution and revenue contribution as a percentage of our total revenue from contracts with customers of our largest customer, our top five customers and our top ten customers for Fiscal 2025, Fiscal 2024 and Fiscal 2023:

Particulars	Fiscal 2025		Fiscal 2024		Fiscal 2023	
	In ₹ lakhs	As a percentage of revenue from operations (%)	In ₹ lakhs	As a percentage of revenue from operations (%)	In ₹ lakhs	As a percentage of revenue from operations (%)
Revenue from operations	27,470.82	100.00%	28,034.03	100.00%	25,912.93	100.00%
Largest customer	1,098.07	4.00%	1,000.11	3.57%	1,180.26	4.55%
Top 5 customers	4,627.42	16.84%	4,605.22	16.43%	4,946.03	19.09%
Top 10 customers	7,854.08	28.59%	7,942.40	28.33%	8,139.00	31.41%

- Regulatory risk:** The pharmaceutical industry is a highly regulated and is subject to government regulations. If we are unable to manage the risks faced by factors such as change in government regulations, our revenues and profits could decline, which could adversely affect our business. We operate in a highly regulated industry and our operations, including our development, testing, manufacturing, marketing and sales activities, are subject to extensive laws and regulations in India and other countries. We are required to obtain and maintain a number of statutory and regulatory permits and approvals under central, state and local government rules in India, including those required by pharmaceutical industry regulators.

- The BRLM associated with the Issue have handled 58 public issues in the past three financial year, out of which 2 issues closed below the issue price on listing date.

Name of the Book Running Lead Manager ("BRLM")	Total Public Issue (Main Board)	Total Public Issues (SME)	Issues Closed below Issue Price on the listing date
Beeline Capital Advisors Private Limited	1	57	2

BID/ISSUE PERIOD

ANCHOR INVESTOR BID/ ISSUE DATE OPENED AND CLOSED ON: FRIDAY, AUGUST 29, 2025
BID/ ISSUE OPENED ON: MONDAY, SEPTEMBER 01, 2025 | BID/ ISSUE CLOSED ON: WEDNESDAY, SEPTEMBER 03, 2025

Continued on next page...

...continued from previous page.

This is an Issue in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR"), read with Regulation 31 of the SEBI ICDR Regulations. The Issue is being made through the Book Building Process in terms of Regulation 6 (1) of the SEBI ICDR Regulations, wherein not more than 50% of the Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs" and such portion, the "QIB Portion"), provided that our Company, in consultation with the BRLM, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"), out of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("Anchor Investor Allocation Price"), in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received from them at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Issue shall be available for allocation to Non-Institutional Bidders ("Non-Institutional Portion") of which one-third of the Non-Institutional Category shall be allocated to Bidders with an application size of more than ₹200,000 and up to ₹1,000,000 and two-thirds of the Non-Institutional Category shall be available for allocation to Bidders with an application size of more than ₹1,000,000 and under-subscription in either of these two sub-categories of Non-Institutional Category may be allocated to Bidders in the other sub-category of Non-Institutional Category in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. Further, not less than 35% of the Issue shall be available for allocation to Retail Individual Investors ("Retail Category"), in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Issue only through the Application Supported by Blocked Amount ("ASBA") process and shall provide details of their respective bank account (including UPI ID (defined hereinafter) in case of UPI Bidders (defined hereinafter) in which the Bid Amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or the Sponsor Bank(s), as the case may be. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. For details, see "Issue Procedure" beginning on page 519 of the Prospectus.

The bidding for Anchor Investor opened and closed on FRIDAY, AUGUST 29, 2025. The Company received 6 applications from 6 Anchor Investors for 47,63,808 Equity Shares. The Anchor Investor Issue Price was finalized at ₹126 per Equity Share. A total of 30,00,000 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 37,80,00,000. The Issue received 1393289 applications for 70,00,000 Equity Shares resulting in 82.73 times subscription. The details of the applications received in the Issue from Retail Individual Bidders, Non-Institutional Bidders and QIBs are as under:

Sr. No.	Category	No. of Applications applied	No. of Equity Shares	Shares Reserved as per Prospectus	No. of times Subscribed	Amount (₹)
A	Retail Individual Bidders	1,314,398	192,825,339	3,500,000	55.0930	24,295,561,339.00
B	Non-Institutional Bidders – More than ₹2 lakhs and upto ₹10 lakhs	51,167	88,990,699	500,000	177.9814	11,212,448,940.00
C	Non-Institutional Bidders – More than ₹10 lakhs	27,698	228,081,826	1,000,000	228.0818	28,738,222,968.00
D	Qualified Institutional Bidders (excluding Anchor Investors)	26	69,235,747	2,000,000	34.6179	8,723,704,122.00
	Total	1,393,289	579,133,611	7,000,000	82.7334	72,969,937,369.00

Final Demand

A summary of the final demand as per NSE and BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	120	573,699	0.09	573,699	0.09
2	121	90,916	0.01	664,615	0.10
3	122	100,198	0.02	764,813	0.12
4	123	140,301	0.02	905,114	0.14
5	124	214,557	0.03	1,119,671	0.18
6	125	297,143	0.05	1,416,814	0.22
7	126	436,616,474	68.77	438,033,288	68.99
8	CUT-OFF	196,864,080	31.01	634,897,368	100.00
	TOTAL	634,897,368	100.00		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being NSE on September 04, 2025.

A. Allotment to Retail Individual Bidders (including ASBA Applications)

The Basis of Allotment to the Retail Individual Bidders, who have bid at cut-off or at the Issue Price of ₹126 per Equity, was finalized in consultation with NSE. This category has been subscribed to the extent of 53.59 times (After Rejection). The total number of Equity Shares Allotted in Retail Individual Bidders category is 35,00,000 Equity Shares to 29411 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted
1	119	1,172,562	91.77	139,534,878	74.40	119	9.391	3,211,929
2	238	55,121	4.31	13,118,798	6.99	119	9.391	151,011
3	357	17,807	1.39	6,357,099	3.39	119	9.391	48,790
4	476	7,962	0.62	3,789,912	2.02	119	9.391	21,777
5	595	6,793	0.53	4,041,835	2.16	119	9.391	18,564
6	714	2,902	0.23	2,072,028	1.10	119	9.391	7,973
7	833	2,585	0.20	2,153,305	1.15	119	9.391	7,021
8	952	996	0.08	948,192	0.51	119	23.996	2,737
9	1071	869	0.07	930,699	0.50	119	20.869	2,380
10	1190	2,457	0.19	2,923,830	1.56	119	9.391	6,664
11	1309	533	0.04	697,697	0.37	119	12.533	1,428
12	1428	546	0.04	779,688	0.42	119	13.546	1,547
13	1547	6,597	0.52	10,205,559	5.44	119	9.391	18,088
14	0	2420	Allottees from Serial no 2 to 13 Additional 1(one) share				91:2420	91
	TOTAL	1,277,730	100.00	187,553,520	100.00			3,500,000

B. Allotment to Non-Institutional Bidders (more than ₹2 lakh and upto ₹10 lakh) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹2 lakh and upto ₹10 lakh), who have bid at the Issue Price of ₹126 per Equity Share or above, was finalized in consultation with NSE. This category has been subscribed to the extent of 174.64 times (after rejection). The total number of Equity Shares allotted in this category is 5,00,000 Equity Shares to 300 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per applicant	Ratio	Total No. of Equity Shares allotted
1	1,666	47337	94.23	78,863,442	90.31	1,666	1:167	471,478
2	1,785	719	1.43	1,283,415	1.47	1,677	4:719	6,708
3	1,904	197	0.39	375,088	0.43	1,677	1:197	1,677
4	2,023	193	0.38	390,439	0.45	1,677	1:193	1,677
5	2,142	122	0.24	261,324	0.30	1,677	1:122	1,677
6	2,380	278	0.55	661,640	0.76	1,677	2:278	3,354
7	2,499	95	0.19	237,405	0.27	1,677	1:95	1,677
8	3,332	176	0.35	586,432	0.67	1,677	1:176	1,677
9	3,927	362	0.72	1,421,574	1.63	1,677	2:362	3,354
10	2,261	75	0.15	169,575	0.19	1,677	0:75	0
11	2,618	31	0.06	81,158	0.09	1,677	0:31	0
12	2,737	38	0.08	104,006	0.12	1,677	0:38	0
13	2,856	24	0.05	68,544	0.08	1,677	0:24	0
14	2,975	37	0.07	110,075	0.13	1,677	0:37	0
15	3,094	46	0.09	142,324	0.16	1,677	0:46	0
16	3,213	49	0.10	157,437	0.18	1,677	0:49	0
17	3,451	35	0.07	120,785	0.14	1,677	0:35	0
18	3,570	53	0.11	189,210	0.22	1,677	0:53	0
19	3,689	11	0.02	40,579	0.05	1,677	0:11	0
20	3,808	16	0.03	60,928	0.07	1,677	0:16	0
21	4,046	45	0.09	182,070	0.21	1,677	0:45	0
22	4,165	18	0.04	74,970	0.09	1,677	0:18	0
23	4,284	8	0.02	34,272	0.04	1,677	0:8	0
24	4,403	2	0.00	8,806	0.01	1,677	0:2	0
25	4,522	5	0.01	22,610	0.03	1,677	0:5	0
26	4,641	4	0.01	18,564	0.02	1,677	0:4	0
27	4,760	23	0.05	109,480	0.13	1,677	0:23	0
28	4,879	7	0.01	34,153	0.04	1,677	0:7	0
29	4,998	29	0.06	144,942	0.17	1,677	0:29	0
30	5,117	4	0.01	20,468	0.02	1,677	0:4	0
31	5,236	1	0.00	5,236	0.01	1,677	0:1	0
32	5,355	10	0.02	53,550	0.06	1,677	0:10	0
33	5,474	8	0.02	43,792	0.05	1,677	0:8	0
34	5,593	1	0.00	5,593	0.01	1,677	0:1	0
35	5,712	2	0.00	11,424	0.01	1,677	0:2	0
36	5,831	2	0.00	11,662	0.01	1,677	0:2	0
37	5,950	28	0.06	166,600	0.19	1,677	0:28	0
38	6,069	5	0.01	30,345	0.03	1,677	0:5	0
39	6,188	1	0.00	6,188	0.01	1,677	0:1	0
40	6,307	6	0.01	37,842	0.04	1,677	0:6	0
41	6,426	6	0.01	38,556	0.04	1,677	0:6	0
42	6,545	8	0.02	52,360	0.06	1,677	0:8	0
43	6,664	16	0.03	106,624	0.12	1,677	0:16	0
44	6,783	1	0.00	6,783	0.01	1,677	0:1	0
45	6,902	1	0.00	6,902	0.01	1,677	0:1	0
46	7,021	4	0.01	28,084	0.03	1,677	0:4	0
47	7,140	11	0.02	78,540	0.09	1,677	0:11	0
48	7,259	3	0.01	21,777	0.02	1,677	0:3	0
49	7,378	1	0.00	7,378	0.01	1,677	0:1	0
50	7,497	5	0.01	37,485	0.04	1,677	0:5	0
51	7,735	7	0.01	54,145	0.06	1,677	0:7	0
52	7,854	68	0.14	534,072	0.61	1,677	0:68	0
53	0						4:755	6,708
54	0						13:17	13
	TOTAL	50,234	100.00	87,320,653	100.00			500,000

C. Allotment to Non-Institutional Bidders (more than ₹10 lakh) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹10 lakh), who have bid at the Issue Price of ₹126 per Equity Share or above, was finalized in consultation with NSE. This category has been subscribed to the extent of 226.38 times (after rejection). The total number of Equity Shares allotted in this category is 10,00,000 Equity Shares to 600 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per applicant	Ratio	Total No. of Equity Shares allotted
1	7,973	26,207	95.34	208,948,411	92.30	1,666	6:275	952,952
2	8,092	329	1.20	2,662,268	1.18	1,666	7:329	11,662
3	8,211	152	0.55	1,248,072	0.55	1,666	3:152	4,998
4	8,330	202	0.73	1,682,660	0.74	1,666	4:202	6,664
5	8,449	57	0.21	481,593	0.21	1,666	1:57	1,666
6	8,568	46	0.17	394,128	0.17	1,666	1:46	1,666
7	8,687	34	0.12	295,358	0.13	1,666	1:34	1,666
8	8,806	26	0.09	228,956	0.10	1,666	1:26	1,666
9	8,925	31	0.11	276,675	0.12	1,666	1:31	1,666
10	9,639	32	0.12	308,448	0.14	1,666	1:32	1,666
11	11,900	51	0.19	606,900	0.27	1,666	1:51	1,666
12	15,946	23	0.08	366,758	0.16	1,666	1:23	1,666
13	18,088	23	0.08	416,024	0.18	1,666	1:23	1,666

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per applicant	Ratio	Total No. of Equity Shares allotted
14	18,445	26	0.09	479,570	0.21	1,666	1:26	1,666
15	9,044	8	0.03	72,352	0.03	1,666	0:8	0
16	9,163	20	0.07	183,260	0.08	1,666	0:20	0
17	9,282	1	0.00	9,282	0.00	1,666	0:1	0
18	9,401	16	0.06	150,416	0.07	1,666	0:16	0
19	9,520	16	0.06					